How to Choose Prenatal Genetic Testing After ACOG's 2026 Update

In January 2026, the American College of Obstetricians and Gynecologists published a Practice Advisory that changes how prenatal genetic screening conversations should start. ACOG endorsed Society for Maternal-Fetal Medicine (SMFM) Consult Series #74 on cell-free DNA (cfDNA) screening — also called NIPT or NIPS — and that package replaces ACOG Practice Bulletin No. 226. The headline for parents: cfDNA screening for common aneuploidies (trisomies 21, 18, and 13) should be routinely available to all obstetrical patients, not only people labeled "high risk," and every patient still has the right to pursue or decline testing after pretest counseling.

That is the shopping filter for this week. It is not a reason to order every add-on panel a lab will sell. SMFM/ACOG are explicit about what belongs in a default conversation and what should stay opt-in or off the routine menu — especially sex chromosome aneuploidies, microdeletion panels, and genome-wide copy-number screens.

A second signal landed days ago. On September 8, 2026, ARUP Laboratories published research in Genetics in Medicine on atypical cfDNA findings — results that are not a clean positive or negative for the common trisomies. In 204 atypical cases with follow-up testing, 50% had at least one abnormal diagnostic finding. The authors' practical message: atypical results should not be shrugged off, and maternal findings are part of the differential. That study is not a product ranking. It is a decision-tree update for what to ask when a portal message is "atypical" or "nonreportable" instead of a clear screen-positive.

This guide is by the ParentRankings Editorial Team. Ranked by parents. For parents. We may be paid by companies we feature. This may influence rankings. Use the checklist first; then compare cards. Full shortlist: Best Prenatal Genetic Testing Services.

Why a how-to beats another "best of" list right now

A classic Top 5 post ranks stars. Parents shopping after the January 2026 Practice Advisory need a decision tree:

1. Do you want screening (risk estimate from maternal blood) or are you already headed toward diagnostic testing (CVS or amniocentesis)?
2. For screening, are you prioritizing common trisomies (21/18/13) — the GRADE 1B routine offer — or also considering sex chromosome aneuploidies as an opt-in after counseling?
3. Are you being sold routine microdeletion or genome-wide CNV screening that SMFM/ACOG do not recommend for the general population?
4. If results come back atypical or nonreportable, do you have a plan that includes counseling, ultrasound, and diagnostic options — consistent with both the Practice Advisory and the September 8, 2026 ARUP findings?
5. Do you need carrier screening (parental gene status) in the same lab ecosystem as NIPT, or is your priority a specialty NIPT with counseling built in?

Natera announced on May 26, 2026 an enhanced Panorama NIPT using SNP-informed deep sequencing, with published low-fetal-fraction performance and a reported 0.5% no-call rate in its validation study. That is useful context for our Best Overall card — especially if redraws or no-calls have been a pain point — but it does not change the ACOG rule that a screen-positive still needs diagnostic confirmation.

Step-by-step: choose before you click "order"

1. Write your use case in one sentence

Examples that stay honest:

• "We want the most sensitive screening for trisomies 21, 18, and 13 that ACOG says should be routinely available, with counseling before we decide on sex-chromosome add-ons."
• "We are having twins and want first-line cfDNA for trisomy 21 per the 2026 endorsement, knowing SCA screening in twins is not recommended."
• "We want transparent self-pay pricing and a large carrier panel more than the broadest rare-chromosomal NIPT menu."
• "We need a nationwide draw site and EHR-friendly ordering more than a specialty genetics portal."

If your sentence is "so we can skip amnio forever," rewrite it. ACOG/SMFM still recommend diagnostic testing after a positive cfDNA result.

2. Separate NIPT screening from carrier screening

These are different jobs that get bundled in marketing:

• NIPT / cfDNA: estimates fetal aneuploidy risk from placental DNA in maternal blood.
• Carrier screening: checks whether you or your partner carry variants that could affect a child (CF, SMA, and expanded panels).

Our shortlist mixes NIPT-forward services (Natera Panorama, LabCorp Integrated Genetics) with carrier-heavy options (Invitae Prenatal, Quest Carrier Screening, Myriad Foresight). Match the card to the job. Ordering a huge carrier panel does not replace trisomy screening — and a trisomy NIPT does not replace carrier counseling.

3. Apply the January 2026 ACOG / SMFM menu rules

From the Practice Advisory (endorsing SMFM Consult #74):

• Routinely available: cfDNA for trisomies 21, 18, and 13 for all obstetrical patients.
• Most sensitive/specific screen for those common aneuploidies in any patient population — still after counseling, with the right to decline.
• Sex chromosome aneuploidies: available as opt-in with appropriate pretest counseling — not an automatic add-on you barely notice on a form.
• Microdeletions: not recommended as routine general-population screening. Patients interested in fetal copy-number risk should be offered diagnostic testing rather than cfDNA microdeletion panels as the default path. 22q11.2 specifically only after counseling if pursued.
• Twins: cfDNA recommended as first-line for trisomy 21; trisomy 18/13 screening recommended with the data caveats in the consult. SCA in twins and higher-order multiples: not recommended.
• Genome-wide large CNV screening via cfDNA: not recommended routinely.

If a sales page treats microdeletion or genome-wide screens as "standard," that is a red flag relative to current ACOG-endorsed guidance.

4. Plan for positive, nonreportable, and atypical results

The Practice Advisory: a positive cfDNA result should be followed by genetic counseling, a detailed anatomic survey, and a recommendation for diagnostic testing (CVS or amniocentesis). Nonreportable results also warrant counseling, comprehensive ultrasound, and diagnostic testing because of increased aneuploidy risk — redraw-only is not automatic.

The ARUP September 8, 2026 study adds texture for atypical findings: in their series, half of atypical cases with follow-up had at least one abnormal diagnostic result, including pathogenic findings and a notable share of maternal findings. Ask your clinician how this lab defines atypical vs nonreportable, what maternal testing options exist before invasive procedures, and who calls you with results.

5. Ask about fetal fraction, no-calls, and turnaround

Low fetal fraction is a known hard case for NIPT. Natera's May 26, 2026 Panorama enhancement specifically markets clinically validated performance at low fetal fraction and a 0.5% no-call rate in its study of 3,323 patients. Use that as a question for any lab: what is your no-call / redraw rate, what happens at low fetal fraction, and how do you counsel after a no-call given the Practice Advisory?

6. Price and insurance — get numbers before the draw

Insurance often covers NIPT and carrier screening, but self-pay and denial pathways vary. Invitae built its prenatal reputation on flatter self-pay pricing (from about $250 on our ranking). Myriad Foresight's self-pay is higher (~$349 on our card). Natera and LabCorp/Quest paths often run through insurance with variable out-of-pocket. Ask for: CPT codes, prior-auth likelihood, and the self-pay ceiling if insurance says no.

7. Only then compare the shortlist cards

Our editors score accuracy, turnaround, genetic counseling support, comprehensiveness, and value. Translate scores into the checklist above. Then open the five cards — they are the only services we discuss as ranked picks.

What to look for in prenatal genetic testing after the 2026 update

We score this category on accuracy, turnaround time, genetic counseling support, comprehensiveness, and value. After January 2026, map those dimensions to shopping questions:

• Accuracy: For common trisomies, prefer labs that publish performance clearly — including hard cases like low fetal fraction — and remember screening is not diagnosis.
• Turnaround: Ask for typical days-to-result and what happens during volume spikes.
• Counseling support: Pretest counseling is part of the ACOG/SMFM standard; post-result access matters even more after atypical or positive findings.
• Comprehensiveness: Broader is not always better. Microdeletion and genome-wide cfDNA add-ons conflict with routine-use guidance even when a lab can run them.
• Value: Include counseling access, redraw policies, and self-pay transparency — not only the sticker on a brochure.

Five checks that do not fit a single score

1. Menu matches ACOG/SMFM: routine 21/18/13; SCA opt-in; no pressure for routine microdeletion/genome-wide CNV screens.
2. Positive / nonreportable / atypical pathways documented before the draw.
3. Carrier vs NIPT jobs clearly separated on the order form.
4. Twin or multifetal status handled per the consult (not a one-size portal).
5. Insurance + self-pay ceiling known before the phlebotomist opens the kit.

We do not invent clinicians, parent testimonials, or credentials. Scores come from the methodology on the category page and the ranking data behind the cards.

Who should use which card after the checklist

Want a specialty NIPT with broad published performance and counseling integrated. Start with Natera Panorama (Best Overall). The May 2026 low-fetal-fraction / low no-call enhancement is relevant if redraws worry you — still confirm positives diagnostically.

Want clinical-lab scale and nationwide processing with strong insurance pursuit. LabCorp Integrated Genetics is the runner-up path: broad OB adoption, first-trimester options alongside NIPT, and infrastructure that reduces shipping friction.

Want transparent self-pay and a huge carrier panel. Invitae Prenatal (Best Value) is the cost-clarity pick — especially when carrier screening is the primary job and you refuse surprise bills.

Need a nearby draw site and EHR-simple ordering for carrier screening. Quest Diagnostics Carrier Screening wins on footprint (thousands of patient service centers) even when counseling depth lags specialty labs.

Want one of the broadest expanded carrier panels with residual-risk reporting. Myriad Genetics Foresight is the depth pick when exhaustive carrier coverage matters more than the lowest self-pay price.

Sensible combos inside this ranking: Panorama (or LabCorp NIPT path) for trisomy screening plus Invitae/Myriad/Quest for carrier panels when your clinician splits the jobs; keep microdeletion "upsells" off the cart unless counseling explicitly supports a narrow exception.

FAQ-minded decisions before the blood draw

Print or save: your one-sentence use case; whether SCA is opt-in or declined; that microdeletion/genome-wide CNV screens are not routine per ACOG/SMFM; who calls on positive, nonreportable, or atypical results; and your self-pay ceiling. If a portal result says "atypical," remember the September 8, 2026 ARUP signal — ask about follow-up yield and maternal testing before assuming the finding is noise.

Guidelines change. Sales pages lag. Set the clinical menu from ACOG/SMFM first, verify claims second, then use the shortlist — and when you are ready to compare all five services side by side, See all 5 Best Prenatal Genetic Testing Services ranked →.